0001140361-16-088355.txt : 20161201 0001140361-16-088355.hdr.sgml : 20161201 20161201143501 ACCESSION NUMBER: 0001140361-16-088355 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161129 FILED AS OF DATE: 20161201 DATE AS OF CHANGE: 20161201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHANNON TIMOTHY M CENTRAL INDEX KEY: 0001207114 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 162027885 MAIL ADDRESS: STREET 1: C/O CURAGEN CORP STREET 2: 555LONG WHARF DR. 11TH FL. CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 doc1.xml FORM 4 X0306 4 2016-11-29 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001207114 SHANNON TIMOTHY M 285 RIVERSIDE AVENUE SUITE 250 WESTPORT CT 06880 1 0 0 0 Common Stock 2016-11-29 4 S 0 22086 11.1839 D 3244381 I See Footnote Common Stock 448 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 - $11.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held directly by Canaan IX L.P. The Reporting Person is a non-managing member of Canaan Partners IX LLC, the general partner of Canaan IX L.P. The Reporting Person does not have voting, investment or dispositive power over any of the shares directly held by Canaan IX L.P. and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Of these 448 shares of Common Stock, 180 of these shares of Common Stock were previously reported by the Reporting Person as indirectly beneficially owned. These shares became directly beneficially owned by the Reporting Person following pro rata distributions of shares on November 30, 2016 by Canaan IX L.P. and Canaan Partners IX LLC, which were exempt from Section 16 of the Exchange Act under Rule 16a-13. /s/ Cynthia J. Ladd, as Attorney-in-Fact for Timothy Shannon 2016-12-01